Participant characteristics
Clinical parameters . | N = 20 (%) . |
---|---|
Sex | |
Male | 7 (35%) |
Female | 13 (65%) |
Age median (range) | 43.5 (19-62) |
Genotype before HSCT | |
AA | 3 (15%) |
AS | 6 (30%) |
SS | 3 (15%) |
Sβ+ | 1 (5%) |
SC | 2 (10%) |
Genotype SCD after HSCT (N = 5), SS | 5 (100%) |
Alpha globin gene mutation | |
Single mutation | 10 (50%) |
No mutation detected | 10 (50%) |
Hematologic data at time of enrollment (mean, SD) | |
WBC (K/mcL) | 6.6 ± 3.1 |
RBC (M/mcL) | 4.0 ± 0.9 |
Hemoglobin (g/dL) | 11.5 ± 2.3 |
Hematocrit (%) | 34.2 ± 7.5 |
MCV (fL) | 85.9 ± 7.6 |
Platelet count (K/mcL) | 308.2 ± 116.4 |
ARC (K/mcL) | 125.8 ± 82.2 |
HbF (%) | 3.2 ± 6.4 |
HbA (%) | 48.2 ± 32.9 |
HbA2 (%) | 3.2 ± 0.5 |
HbS (%) | 41.2 ± 24.1 |
HbC (%) | 43.2 ± 0 |
AST (U/L) | 22.6 ± 8.8 |
Total bilirubin (mg/dL) | 1.0 ± 0.9 |
LDH (U/L) | 254.2 ± 111.2 |
Study duration mean number of days (range) | 103 (35-147) |
Clinical parameters . | N = 20 (%) . |
---|---|
Sex | |
Male | 7 (35%) |
Female | 13 (65%) |
Age median (range) | 43.5 (19-62) |
Genotype before HSCT | |
AA | 3 (15%) |
AS | 6 (30%) |
SS | 3 (15%) |
Sβ+ | 1 (5%) |
SC | 2 (10%) |
Genotype SCD after HSCT (N = 5), SS | 5 (100%) |
Alpha globin gene mutation | |
Single mutation | 10 (50%) |
No mutation detected | 10 (50%) |
Hematologic data at time of enrollment (mean, SD) | |
WBC (K/mcL) | 6.6 ± 3.1 |
RBC (M/mcL) | 4.0 ± 0.9 |
Hemoglobin (g/dL) | 11.5 ± 2.3 |
Hematocrit (%) | 34.2 ± 7.5 |
MCV (fL) | 85.9 ± 7.6 |
Platelet count (K/mcL) | 308.2 ± 116.4 |
ARC (K/mcL) | 125.8 ± 82.2 |
HbF (%) | 3.2 ± 6.4 |
HbA (%) | 48.2 ± 32.9 |
HbA2 (%) | 3.2 ± 0.5 |
HbS (%) | 41.2 ± 24.1 |
HbC (%) | 43.2 ± 0 |
AST (U/L) | 22.6 ± 8.8 |
Total bilirubin (mg/dL) | 1.0 ± 0.9 |
LDH (U/L) | 254.2 ± 111.2 |
Study duration mean number of days (range) | 103 (35-147) |
AST, aspartate transaminase; HbA, adult hemoglobin; HbA2, hemoglobin A2; HbC, hemoglobin C; HbS, sickle hemoglobin; MCV, mean corpuscular volume; WBC, white blood cell count.